Androgen induction of prostate cancer cell invasion is mediated by ezrin

被引:72
作者
Chuan, Yin-Choy
Pang, See-Tong
Cedazo-Minguez, Angel
Norstedt, Gunnar
Pousette, Ake
Flores-Morales, Amilcar
机构
[1] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Neurotec, Sect Expt Geriatr, S-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Med, Androl Ctr, S-17176 Stockholm, Sweden
[4] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Surg,Div Urol, Tao Yuan 333, Taiwan
关键词
D O I
10.1074/jbc.M602237200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ezrin is a key signaling molecule that regulates cell survival, adhesion migration, and invasion. We have previously shown that ezrin is regulated by androgen in rat prostate and that its expression is increased in prostate cancer and in prostate intraepithelial neoplasia. We have used the androgen-sensitive cell line LNCaP-FGC to investigate the role of ezrin in androgen-induced cell invasion. We found that androgen treatment of LNCaP-FGC cells induces ezrin expression, an effect that is inhibited by the androgen receptor antagonist, bicalutamide. In addition, androgen treatment induces the phosphorylation of ezrin in Thr-567 and Tyr-353 in a sequential manner. This is mediated through protein kinase C alpha and Src tyrosine kinase, respectively. Androgen treatment induces the translocation of both protein kinase C alpha and ezrin to the cell membrane and their association. Inhibition of ezrin function using short interference RNA or the overexpression of T567A and Y353F-ezrin mutants significantly reduces androgen-induced Matrigel invasion but does not affect cell proliferation or cell adhesion. Matrigel invasion of the androgen-insensitive prostate cancer cell lines PC-3 and LNCaP-R is also dependent on ezrin. In summary, we have shown that androgens regulate ezrin at transcriptional and posttranscriptional levels. Hormonal regulation of ezrin phosphorylation is required for androgen-induced cell invasion.
引用
收藏
页码:29938 / 29948
页数:11
相关论文
共 57 条
[1]   High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential [J].
Akisawa, N ;
Nishimori, I ;
Iwamura, T ;
Onishi, S ;
Hollingsworth, MA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 258 (02) :395-400
[2]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[3]   Androgen receptor expression in prostate carcinoma cells suppresses α6β4 integrin-mediated invasive phenotype [J].
Bonaccorsi, L ;
Carloni, V ;
Muratori, M ;
Salvadori, A ;
Giannini, A ;
Carini, M ;
Serio, R ;
Forti, G ;
Baldi, E .
ENDOCRINOLOGY, 2000, 141 (09) :3172-3182
[4]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[5]   Metastatic prostate carcinoma to bone - Clinical and pathologic features associated with cancer-specific survival [J].
Cheville, JC ;
Tindall, D ;
Boelter, C ;
Jenkins, R ;
Lohse, CM ;
Pankratz, VS ;
Sebo, TJ ;
Davis, B ;
Blute, ML .
CANCER, 2002, 95 (05) :1028-1036
[6]   Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells [J].
Crepaldi, T ;
Gautreau, A ;
Comoglio, PM ;
Louvard, D ;
Arpin, M .
JOURNAL OF CELL BIOLOGY, 1997, 138 (02) :423-434
[7]   Ezrin ... a metastatic detERMinant? [J].
Curto, M ;
McClatchey, AI .
CANCER CELL, 2004, 5 (02) :113-114
[8]   6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial [J].
D'Amico, AV ;
Manola, J ;
Loffredo, M ;
Renshaw, AA ;
DellaCroce, A ;
Kantoff, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07) :821-827
[9]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[10]   The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways [J].
Edwards, J ;
Bartlett, JMS .
BJU INTERNATIONAL, 2005, 95 (09) :1327-1335